Last deal

$5.M

Amount

Seed

Stage

12.08.2024

Date

2

all rounds

$7.1M

Total amount

General

About Company
Kano Therapeutics enables safe, effective, and flexible correction of gene-length stretches of DNA through a new class of biomaterials.

founded date

2021

Number of employees

Company Type

For Profit

Last funding type

Seed

IPO status

Private

Description

Developer of a biotechnological production platform intended to expand the reach of genome-editing-based therapies through the development of transformational biomaterials. The company uses DNA nanotechnology and synthetic biology to design and engineer novel gene vectors that carry genetic information, providing pharmaceutical and synthetic biology companies with gene delivery and vaccine construct knowledge.
Contacts